Table 1.
Clinical, anthropometric and laboratory characteristics of studied groups
| Control group (mean ± SD) (n = 40) |
PCO patients (mean ± SD) (n = 60) |
P | |
|---|---|---|---|
| Systolic blood pressure (mm Hg) | 125.4 ± 7.16 | 130.6 ± 7.3 | <0.001* |
| Diastolic blood pressure (mm Hg) | 85.6 ± 3.96 | 87.5 ± 4.9 | <0.001* |
| Hirsutism score | 5.38 ± 0.594 | 7.41 ± 3.02 | <0.001* |
| Body mass index (kg/m2) | 24.9 ± 2.48 | 33.2 ± 5.731 | <0.001* |
| Waist/hip ratio | 0.98 ± 0.191 | 1.26 ± 0.28 | <0.001* |
| Ovarian volume | 3.58 ± 0.612 | 7.35 ± 2.744 | <0.001* |
| AFC | 2.58 ± 0.612 | 7.35 ± 2.744 | <0.001* |
| Total cholesterol (mg/dL) | 167.5 ± 19.26 | 185.0 ± 124.7 | <0.001* |
| Triglycerides (mg/dL) | 144.55 ± 20.4 | 192.2 ± 42.05 | <0.001* |
| LDL cholesterol (mg/dL) | 106.24 ± 4.24 | 125.8 ± 18.11 | <0.001* |
| HDL cholesterol (mg/dL) | 57.5 ± 7.33 | 40.3 ± 9.42 | <0.001* |
| Fasting plasma glucose (mg/dL) | 83.9 ± 8.40 | 95.3 ± 15.61 | <0.001* |
| HbA1c (%) | 5.5 ± 0.596 | 6.03 ± 0.42 | <0.001* |
| Fasting serum insulin (lU/mL) | 6.8 ± 1.44 | 17.5 ± 10.41 | <0.001* |
| HOMA-IR | 1.42 ± 0.322 | 3.7 ± 2.32 | <0.001* |
| HOMA-β | 166.9 ± 76.9 | 127.7 ± 81.84 | 0.016 |
| FSH (mIU/mL) | 4.8 ± 0.972 | 5.5 ± 1.538 | <0.001* |
| LH (mIU/mL) | 5.52 ± 1.21 | 6.97 ± 1.53 | <0.001* |
| LH/FSH | 1.2 ± 0.43 | 13 ± 0.39 | 0.145 |
| DHEA-S (mg/mL) | 0.99 ± 0.31 | 1.3 ± 0.77 | <0.001* |
| Androstenedione (ng/mL) | 1.17 ± 0.34 | 1.7 ± 0.5 | 0.015 |
| Total testosterone (ng/mL) | 0.50 ± 0.145 | 0.7 ± 0.32 | <0.001* |
FSI fasting serum insulin, FPG fasting plasma glucose, AFC antral follicle cells, HOMA-IR homeostasis model assessments of insulin resistance, DHEA dehydroepiandrosterone, *P < 0.05 when compared with control group